CVRx, Inc. (CVRX)

Market Cap	319.36M
Revenue (ttm)	39.30M
Net Income (ttm)	-41.20M
Shares Out	20.93M
EPS (ttm)	-1.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,137
Open	15.79
Previous Close	15.71
Day's Range	15.25 - 15.99
52-Week Range	9.08 - 33.14
Beta	1.23
Analysts	Strong Buy
Price Target	33.67 (+120.64%)
Earnings Date	Apr 30, 2024

About CVRX

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 an...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 30, 2021
• Employees: 200
• Stock Exchange: NASDAQ
• Ticker Symbol: CVRX

Financial Performance

In 2023, CVRx, Inc.'s revenue was $39.30 million, an increase of 74.89% compared to the previous year's $22.47 million. Losses were -$41.20 million, -0.55% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for CVRX stock is "Strong Buy." The 12-month stock price forecast is $33.67, which is an increase of 120.64% from the latest price.

Price Target

$33.67

(120.64% upside)

Analyst Consensus: Strong Buy